↓ Skip to main content

Predicting methotrexate resistance in rheumatoid arthritis patients

Overview of attention for article published in Inflammopharmacology, March 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
51 Mendeley
Title
Predicting methotrexate resistance in rheumatoid arthritis patients
Published in
Inflammopharmacology, March 2018
DOI 10.1007/s10787-018-0459-z
Pubmed ID
Authors

Mary Beth Yu, Anthony Firek, William H. R. Langridge

Abstract

Rheumatoid arthritis (RA) is an incurable, systemic autoimmune disease that decreases quality of life and can lead to severe disability. While there are many medications available to treat RA, the first-line of therapy is low-dose methotrexate (MTX), a small molecule disease-modifying anti-rheumatic drug (DMARD). MTX is the recommended therapy due to its affordability and efficacy in reducing symptoms in most RA patients. Unfortunately, there is great person-to-person variability in the physiological response to MTX, with up to 50% of patients showing little response to the medication. Thus, many RA patients initially placed on MTX do not experience an adequate reduction of symptoms, and could have benefited more in both the short and long terms if initially prescribed a different drug that was more effective for them. To combat this problem and better guide treatment decisions, many research groups have attempted to develop predictive tools for MTX response. Currently, there is no reliable, clinical-grade method to predict an individual's response to MTX treatment. In this review, we describe progress made in the area of MTX non-response/resistance in RA patients. We specifically focus on application of the following elements as predictive markers: proteins related to MTX transport and function, intracellular MTX concentration, immune cell frequencies, cytokines, and clinical factors.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 16%
Researcher 6 12%
Other 4 8%
Student > Master 4 8%
Student > Bachelor 3 6%
Other 6 12%
Unknown 20 39%
Readers by discipline Count As %
Medicine and Dentistry 14 27%
Biochemistry, Genetics and Molecular Biology 5 10%
Immunology and Microbiology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Agricultural and Biological Sciences 2 4%
Other 2 4%
Unknown 20 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2018.
All research outputs
#13,936,964
of 23,105,443 outputs
Outputs from Inflammopharmacology
#275
of 544 outputs
Outputs of similar age
#178,924
of 332,855 outputs
Outputs of similar age from Inflammopharmacology
#10
of 24 outputs
Altmetric has tracked 23,105,443 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 544 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,855 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.